Complications of chemotherapy for prostate cancer

Tomasz (Tom) Beer, Joseph Bubalo

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    To date, all available therapies for prostate cancer are plagued by adverse effects. Chemotherapy is no exception. The mechanisms of activity of chemotherapy agents are not cancer-specific. Normal tissues, particularly those that require rapid cell proliferation, are vulnerable to the effects of growth inhibition by these cytotoxic agents. Furthermore, both predictable as well as idiosyncratic toxicities unrelated to the antineoplastic activity of these agents can occur. In some cases, the cause of adverse events may be linked to the vehicle required to suspend water-insoluble chemotherapy drugs. Patient-specific factors can also significantly contribute to the risk of chemotherapy side-effects. However, with optimal clinical care the toxicity of antineoplastic agents can be substantially reduced. Long before chemotherapy is contemplated, it is imperative to limit treatments that reduce patients' capacity to tolerate subsequent chemotherapy. Moreover, offering treatment before patients' performance status declines can significantly improve tolerance of treatment. Once chemotherapy is initiated, the incidence and severity of adverse effects can be reduced through individualized selection of chemotherapy regimens and appropriate use of adjunct medications. Finally, aggressive management of toxicities after they occur lessens their duration and severity. The common toxicities of current chemotherapy regimens for prostate cancer, as well as strategies to limit and manage these toxicities are reviewed.

    Original languageEnglish (US)
    Pages (from-to)222-230
    Number of pages9
    JournalSeminars in Urologic Oncology
    Volume19
    Issue number3
    StatePublished - 2001

    Fingerprint

    Prostatic Neoplasms
    Drug Therapy
    Antineoplastic Agents
    Cytotoxins
    Therapeutics
    Cell Proliferation
    Water
    Incidence
    Growth
    Pharmaceutical Preparations

    Keywords

    • Adverse effects
    • Chemotherapy
    • Complications
    • Prostate cancer
    • Toxicity

    ASJC Scopus subject areas

    • Urology

    Cite this

    Complications of chemotherapy for prostate cancer. / Beer, Tomasz (Tom); Bubalo, Joseph.

    In: Seminars in Urologic Oncology, Vol. 19, No. 3, 2001, p. 222-230.

    Research output: Contribution to journalArticle

    Beer, Tomasz (Tom) ; Bubalo, Joseph. / Complications of chemotherapy for prostate cancer. In: Seminars in Urologic Oncology. 2001 ; Vol. 19, No. 3. pp. 222-230.
    @article{6c710f3e72c54d38b27530b041db5b48,
    title = "Complications of chemotherapy for prostate cancer",
    abstract = "To date, all available therapies for prostate cancer are plagued by adverse effects. Chemotherapy is no exception. The mechanisms of activity of chemotherapy agents are not cancer-specific. Normal tissues, particularly those that require rapid cell proliferation, are vulnerable to the effects of growth inhibition by these cytotoxic agents. Furthermore, both predictable as well as idiosyncratic toxicities unrelated to the antineoplastic activity of these agents can occur. In some cases, the cause of adverse events may be linked to the vehicle required to suspend water-insoluble chemotherapy drugs. Patient-specific factors can also significantly contribute to the risk of chemotherapy side-effects. However, with optimal clinical care the toxicity of antineoplastic agents can be substantially reduced. Long before chemotherapy is contemplated, it is imperative to limit treatments that reduce patients' capacity to tolerate subsequent chemotherapy. Moreover, offering treatment before patients' performance status declines can significantly improve tolerance of treatment. Once chemotherapy is initiated, the incidence and severity of adverse effects can be reduced through individualized selection of chemotherapy regimens and appropriate use of adjunct medications. Finally, aggressive management of toxicities after they occur lessens their duration and severity. The common toxicities of current chemotherapy regimens for prostate cancer, as well as strategies to limit and manage these toxicities are reviewed.",
    keywords = "Adverse effects, Chemotherapy, Complications, Prostate cancer, Toxicity",
    author = "Beer, {Tomasz (Tom)} and Joseph Bubalo",
    year = "2001",
    language = "English (US)",
    volume = "19",
    pages = "222--230",
    journal = "Urologic Oncology: Seminars and Original Investigations",
    issn = "1078-1439",
    publisher = "Elsevier Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - Complications of chemotherapy for prostate cancer

    AU - Beer, Tomasz (Tom)

    AU - Bubalo, Joseph

    PY - 2001

    Y1 - 2001

    N2 - To date, all available therapies for prostate cancer are plagued by adverse effects. Chemotherapy is no exception. The mechanisms of activity of chemotherapy agents are not cancer-specific. Normal tissues, particularly those that require rapid cell proliferation, are vulnerable to the effects of growth inhibition by these cytotoxic agents. Furthermore, both predictable as well as idiosyncratic toxicities unrelated to the antineoplastic activity of these agents can occur. In some cases, the cause of adverse events may be linked to the vehicle required to suspend water-insoluble chemotherapy drugs. Patient-specific factors can also significantly contribute to the risk of chemotherapy side-effects. However, with optimal clinical care the toxicity of antineoplastic agents can be substantially reduced. Long before chemotherapy is contemplated, it is imperative to limit treatments that reduce patients' capacity to tolerate subsequent chemotherapy. Moreover, offering treatment before patients' performance status declines can significantly improve tolerance of treatment. Once chemotherapy is initiated, the incidence and severity of adverse effects can be reduced through individualized selection of chemotherapy regimens and appropriate use of adjunct medications. Finally, aggressive management of toxicities after they occur lessens their duration and severity. The common toxicities of current chemotherapy regimens for prostate cancer, as well as strategies to limit and manage these toxicities are reviewed.

    AB - To date, all available therapies for prostate cancer are plagued by adverse effects. Chemotherapy is no exception. The mechanisms of activity of chemotherapy agents are not cancer-specific. Normal tissues, particularly those that require rapid cell proliferation, are vulnerable to the effects of growth inhibition by these cytotoxic agents. Furthermore, both predictable as well as idiosyncratic toxicities unrelated to the antineoplastic activity of these agents can occur. In some cases, the cause of adverse events may be linked to the vehicle required to suspend water-insoluble chemotherapy drugs. Patient-specific factors can also significantly contribute to the risk of chemotherapy side-effects. However, with optimal clinical care the toxicity of antineoplastic agents can be substantially reduced. Long before chemotherapy is contemplated, it is imperative to limit treatments that reduce patients' capacity to tolerate subsequent chemotherapy. Moreover, offering treatment before patients' performance status declines can significantly improve tolerance of treatment. Once chemotherapy is initiated, the incidence and severity of adverse effects can be reduced through individualized selection of chemotherapy regimens and appropriate use of adjunct medications. Finally, aggressive management of toxicities after they occur lessens their duration and severity. The common toxicities of current chemotherapy regimens for prostate cancer, as well as strategies to limit and manage these toxicities are reviewed.

    KW - Adverse effects

    KW - Chemotherapy

    KW - Complications

    KW - Prostate cancer

    KW - Toxicity

    UR - http://www.scopus.com/inward/record.url?scp=0034868459&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0034868459&partnerID=8YFLogxK

    M3 - Article

    C2 - 11561990

    AN - SCOPUS:0034868459

    VL - 19

    SP - 222

    EP - 230

    JO - Urologic Oncology: Seminars and Original Investigations

    JF - Urologic Oncology: Seminars and Original Investigations

    SN - 1078-1439

    IS - 3

    ER -